Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Renagel sevelamer: Pilot study; marketed to reduce serum phosphorus in patients with end-stage renal disease who are on hemodialysis.

GELX and partner Genzyme (GENZ, Cambridge, Mass.)

Read the full 73 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE